---
title: "Day One Biopharmaceuticals (DAWN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DAWN.US.md"
symbol: "DAWN.US"
name: "Day One Biopharmaceuticals"
industry: "Biotechnology"
datetime: "2026-04-30T12:11:17.288Z"
locales:
  - [en](https://longbridge.com/en/quote/DAWN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DAWN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DAWN.US.md)
---

# Day One Biopharmaceuticals (DAWN.US)

## Company Overview

Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-30T04:30:18.000Z

**Overall: C (0.44)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 389 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 20.60% |  |
| Net Profit YoY | -12.38% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 158182000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -22.74% | E |
| Profit Margin | -67.85% | E |
| Gross Margin | 89.12% | A |
| Revenue YoY | 20.60% | B |
| Net Profit YoY | -12.38% | D |
| Total Assets YoY | -12.86% | E |
| Net Assets YoY | -12.25% | E |
| Cash Flow Margin | 96.68% | C |
| OCF YoY | 20.60% | B |
| Turnover | 0.29 | D |
| Gearing Ratio | 13.13% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Day One Biopharmaceuticals",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "20.60%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-12.38%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "158182000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-22.74%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-67.85%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "89.12%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "20.60%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-12.38%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.86%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-12.25%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "96.68%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "20.60%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.29",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "13.13%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -20.73 | 496/389 | - | - | - |
| PB | 5.04 | 315/389 | 2.66 | 1.68 | 1.44 |
| PS (TTM) | 14.06 | 185/389 | 8.83 | 4.53 | 3.99 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | C | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-06T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 8 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 21.49 |
| Highest Target | 21.50 |
| Lowest Target | 21.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DAWN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DAWN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/DAWN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/DAWN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**